tazobactam has been researched along with Gram-Negative Bacterial Infections in 56 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.79) | 18.2507 |
| 2000's | 10 (17.86) | 29.6817 |
| 2010's | 28 (50.00) | 24.3611 |
| 2020's | 17 (30.36) | 2.80 |
| Authors | Studies |
|---|---|
| Courvalin, P; Dupêchez, M; Galimand, M; Lambert, T; Meziane-Cherif, D | 1 |
| Cruz-López, F; Garza-González, E; Maldonado-Garza, HJ; Martínez-Meléndez, A; Morfin-Otero, R; Rodriguez-Noriega, E | 1 |
| Aiello, TF; Chumbita, M; Garcia-Vidal, C; Lopera-Mármol, C; Monzo-Gallo, P; Puerta-Alcalde, P | 1 |
| Assanelli, AA; Bernardi, M; Carletti, S; Carrabba, MG; Castagna, A; Ciceri, F; Clerici, D; Corti, C; Erbella, F; Farina, F; Galli, L; Giglio, F; Greco, R; Liberatore, C; Lorentino, F; Lugli, AP; Lupo Stanghellini, MT; Mancini, N; Mastaglio, S; Nitti, R; Oltolini, C; Peccatori, J; Poli, A; Ripa, M; Ruggeri, A; Scarpellini, P; Tassan Din, C; Xue, E | 1 |
| Papp-Wallace, KM | 1 |
| Ang, JY; Arrieta, A; Bradley, JS; Johnson, MG; Rhee, EG; Rizk, ML; Yu, B; Zhang, Z | 1 |
| Carvalhaes, CG; Castanheira, M; Flamm, RK; Sader, HS | 1 |
| Ang, JY; Arrieta, AC; Feng, EH; Johnson, MG; Larson, KB; Rhee, EG; Rizk, ML; Yu, B; Zhang, Z | 1 |
| Cantón, R; Gomes, R; Martins-Oliveira, I; Pérez-Viso, B; Pina-Vaz, C; Quintas, S; Rodrigues, AG; Silva-Dias, A | 1 |
| Bruniera, FR; Costa, SF; Cury, AP; Higashino, H; Mendes, FR; Oliveira, FN; Rizeck, C; Rocha, V; Rossi, F; Schmidt, J | 1 |
| Araj, GF; Berjawi, DM; El Beayni, NK; Musharrafieh, U | 1 |
| Bassetti, M; Battaglini, D; Giacobbe, DR; Pelosi, P; Vena, A | 1 |
| De Ponti, F; Gatti, M; Raschi, E | 1 |
| Carvalhaes, CG; Flamm, RK; Shortridge, D; Streit, JM | 1 |
| Garello, P; Livermore, DM; Mushtaq, S; Vickers, A; Woodford, N | 1 |
| Collings, H; Dillon, R; Enstone, A; Palmer, T; Puzniak, L | 1 |
| Bernardi, M; Castagna, A; Castiglion, B; Ciceri, F; Clerici, D; Corti, C; Farina, F; Giglio, F; Greco, R; Liberatore, C; Lorentino, F; Mastaglio, S; Oltolini, C; Pavesi, F; Peccatori, J; Ripa, M; Scarpellini, P; Tassan Din, C | 1 |
| Bragantini, D; Carrara, E; Cattaneo, P; Chiamenti, M; Ellis, S; Franceschi, F; Giske, CG; Lodise, T; Menchinelli, G; Piddock, LJV; Righi, E; Sanguinetti, M; Savoldi, A; Scudeller, L; Tacconelli, E | 1 |
| Garcia, JA; Liang, SY; Long, B; Matlock, A; Moussavi, K | 1 |
| Adkin, R; Chaudhry, A; Hill, R; Hopkins, KL; Livermore, DM; Meunier, D; Mushtaq, S; Pike, R; Staves, P; Woodford, N | 1 |
| Ahir, H; Foo, J; Merchant, S; Prabhu, V; Sarpong, E | 1 |
| Flamm, RK; Huband, MD; Jones, RN; Riedel, S; Sader, HS | 1 |
| Sinkó, J | 1 |
| Girotto, JE; Nicolau, DP; Rodriguez, BA | 1 |
| Hu, Y; Li, Z; Sun, F; Wang, D; Xu, R | 1 |
| Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR | 1 |
| Ang, JY; Arrieta, AC; Bradley, JS; Caro, L; Johnson, MG; Larson, KB; Rhee, EG; Rizk, ML; Yang, S; Yu, B | 1 |
| Eckmann, C; Lyon, S; Rojas, LJ | 1 |
| Duncan, LR; Flamm, RK; Pfaller, MA; Shortridge, D | 1 |
| Gutiérrez-Gutiérrez, B; Kahlmeter, G; Rodríguez-Baño, J | 1 |
| Berdaï, D; Boyer, A; Prevel, R | 1 |
| Hsu, AJ; Tamma, PD | 1 |
| Jacobus, NV; McDermott, LA; Snydman, DR | 1 |
| Adam, H; Chung, P; Denisuik, A; Gin, AS; Hoban, DJ; Karlowsky, JA; Lagacé-Wiens, PR; Lynch, JP; Rubinstein, E; Schweizer, F; Walkty, A; Zelenitsky, S; Zhanel, GG | 1 |
| Farrell, DJ; Flamm, RK; Jones, RN; Sader, HS | 1 |
| Hong, SK; Kim, EC; Kim, JA | 1 |
| Conte, V; D'Inzeo, T; De Angelis, G; Di Florio, V; Fiori, B; Giani, T; Giaquinto, A; Palucci, I; Rossolini, GM; Sanguinetti, M; Santangelo, R; Scoppettuolo, G; Spanu, T | 1 |
| Eckmann, C; Solomkin, J | 1 |
| Bassetti, M; Righi, E | 1 |
| Baek, JY; Sohn, KM | 1 |
| Du, Y; Guo, W; He, J; He, Q; Wang, Z; Wei, M; Wu, C; Yang, Z | 1 |
| Darouiche, RO; Steenbergen, J; Umeh, O; Wagenlehner, FM; Yuan, G | 1 |
| Hirsch, EB; Liscio, JL; Mahoney, MV | 1 |
| Merluzzi, S; Pagotto, A; Pillinini, P; Valeri, M | 1 |
| Burgess, DS; Frei, CR | 1 |
| Enbawe, S; Lat, A; Lodise, TP; Manor, K; Patel, GW; Patel, N; Smith, R; Trombley, K | 1 |
| Cheatham, SC; Kays, MB; Shea, KM; Smith, DW; Sowinski, KM; Wack, MF | 1 |
| Foley, RJ; Kannan, S; Kourelis, T | 1 |
| Adams, CA; Cioffi, WG; Connolly, MD; Gregg, S; Heffernan, DS; Monaghan, SF; Stephen, A; Thakkar, RK | 1 |
| Apfalter, P; Berger, A; Kretzer, V; Pollak, A; Rohrmeister, K; Zaknun, D | 1 |
| Harada, AS; Lau, W | 1 |
| Erba, P; Hintermann, B; Kalbermatten, DF; Laifer, G; Pierer, G; Rieger, UM; Uike, K | 1 |
| Bennett, KM; Dodds-Ashley, E; Hayward, TZ; Kaye, KS; Scarborough, JE; Sharpe, M; Vaslef, SN | 1 |
| Hanaki, H; Nagayama, A; Nomura, S | 1 |
| Aznar, E; Climent, MA; Máiquez, J; Palau, J; Picón, I | 1 |
| Bonnaure-Mallet, M; Buffet, A; Cormier, M; David, S; Dupuy, C; Jolivet-Gougeon, A; Sixou, JL | 1 |
16 review(s) available for tazobactam and Gram-Negative Bacterial Infections
| Article | Year |
|---|---|
Efficacy and
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Tazobactam | 2022 |
New treatments for multidrug-resistant non-fermenting Gram-negative bacilli Infections.
Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tazobactam | 2022 |
The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Boronic Acids; Cephalosporins; Clinical Trials as Topic; Drug Combinations; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Humans; Meropenem; Tazobactam | 2019 |
Capnocytophaga sputigena bloodstream infection in hematopoietic stem cell transplantations: two cases report and review of the literature.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Capnocytophaga; Gram-Negative Bacterial Infections; Hematopoietic Stem Cell Transplantation; Humans; Meropenem; Middle Aged; Mucositis; Neutrophils; Piperacillin; RNA, Ribosomal, 16S; Sequence Analysis, DNA; Tazobactam; Transplantation, Autologous | 2020 |
The role of new antimicrobials for Gram-negative infections in daily clinical practice.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactams; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Imipenem; Microbial Sensitivity Tests; Polymyxins; Sisomicin; Tazobactam; Tetracyclines | 2020 |
Real-world use of ceftolozane/tazobactam: a systematic literature review.
Topics: Cephalosporins; Comorbidity; Critical Illness; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Pseudomonas Infections; Respiratory Tract Infections; Tazobactam; Urinary Tract Infections | 2021 |
Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Colistin; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Fosfomycin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; In Vitro Techniques; Microbial Sensitivity Tests; Polymyxins; Rifampin; Tazobactam; Tobramycin | 2021 |
Advances in novel antibiotics to treat multidrug-resistant gram-negative bacterial infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Boronic Acids; Cefiderocol; Ceftazidime; Cephalosporins; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Design; Drug Resistance, Multiple; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Humans; Meropenem; Sisomicin; Tazobactam; Tetracyclines | 2021 |
[Clinical aspects of severe infections caused by antibiotic-resistant Gram-negative bacteria. The Empire strikes back?]
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Penicillanic Acid; Tazobactam | 2017 |
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Novel Therapy for Multidrug Resistant Gram Negative Infections in Children.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Child; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Penicillanic Acid; Tazobactam; Treatment Outcome | 2018 |
Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Boronic Acids; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Meropenem; Tazobactam | 2019 |
Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Gram-Negative Bacterial Infections; Humans; Penicillanic Acid; Tazobactam | 2014 |
Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Clinical Trials, Phase III as Topic; Drug Combinations; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Penicillanic Acid; Tazobactam | 2015 |
Delftia lacustris septicemia in a pheochromocytoma patient: case report and literature review.
Topics: Adrenal Gland Neoplasms; Aged; Anti-Bacterial Agents; Bacteremia; Catheter-Related Infections; Delftia; DNA, Bacterial; DNA, Ribosomal; Gram-Negative Bacterial Infections; Humans; Male; Penicillanic Acid; Pheochromocytoma; Piperacillin; RNA, Ribosomal, 16S; Sepsis; Sequence Analysis, DNA; Tazobactam | 2015 |
Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Bacterial; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Penicillanic Acid; Tazobactam | 2015 |
Bloodstream infection with Oligella ureolytica: a case report and review of the literature.
Topics: Aged; Alcaligenaceae; Anti-Bacterial Agents; Aortic Valve Stenosis; Bacteremia; Drug Therapy, Combination; Gram-Negative Bacterial Infections; Humans; Male; Penicillanic Acid; Piperacillin; Risk Factors; Tazobactam; Treatment Outcome | 2016 |
4 trial(s) available for tazobactam and Gram-Negative Bacterial Infections
| Article | Year |
|---|---|
Ceftolozane/Tazobactam in Neonates and Young Infants: The Challenges of Collecting Pharmacokinetics and Safety Data in This Vulnerable Patient Population.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Cephalosporins; Child; Clinical Trials as Topic; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Infant; Infant, Newborn; Infant, Premature; Injections, Intravenous; Male; Preoperative Care; Tazobactam | 2021 |
Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis.
Topics: Administration, Intravenous; Adolescent; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Female; Gram-Negative Bacterial Infections; Humans; Male; Tazobactam | 2020 |
Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection.
Topics: Administration, Intravenous; Adolescent; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infant; Infant, Newborn; Intraabdominal Infections; Male; Tazobactam; Urinary Tract Infections | 2018 |
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).
Topics: Adult; Aged; Anti-Infective Agents, Urinary; Cephalosporins; Double-Blind Method; Drug Administration Schedule; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Infusions, Intravenous; Levofloxacin; Male; Middle Aged; Penicillanic Acid; Pyelonephritis; Tazobactam; Treatment Outcome; Urinary Tract Infections; Young Adult | 2015 |
36 other study(ies) available for tazobactam and Gram-Negative Bacterial Infections
| Article | Year |
|---|---|
Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Base Sequence; beta-Lactamases; Brachyspira; Cloning, Molecular; Diarrhea; Feces; Gram-Negative Bacterial Infections; Humans; Kinetics; Molecular Sequence Data; Oxacillin; Penicillin Resistance; Sequence Analysis, DNA | 2008 |
Levofloxacin prophylaxis vs no prophylaxis in patients with neutropenia within an endemic country for carbapenem-resistant GNB.
Topics: Anti-Infective Agents; Carbapenems; Cohort Studies; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Neutropenia; Piperacillin; Retrospective Studies; Tazobactam; Transplantation, Homologous | 2023 |
Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).
Topics: Academic Medical Centers; Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial; Tazobactam; United States | 2020 |
Evaluation of ultra-rapid susceptibility testing of ceftolozane-tazobactam by a flow cytometry assay directly from positive blood cultures.
Topics: Anti-Bacterial Agents; Blood Culture; Cephalosporins; Flow Cytometry; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Portugal; Spain; Tazobactam | 2020 |
Activity of ceftolozane/tazobactam against commonly encountered antimicrobial resistant Gram-negative bacteria in Lebanon.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Klebsiella pneumoniae; Lebanon; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tazobactam | 2020 |
Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporins; Drug Combinations; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Humans; Lactams; Male; Microbial Sensitivity Tests; Middle Aged; Pancytopenia; Pharmacovigilance; Retrospective Studies; Tazobactam | 2021 |
Susceptibility trends of ceftolozane/tazobactam and comparators when tested against U.S. gram-negative bacterial surveillance isolates (2012-2018).
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Public Health Surveillance; Tazobactam; United States | 2021 |
Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cefepime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tazobactam | 2021 |
The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.
Topics: Adult; Aged; Allografts; Anti-Bacterial Agents; Autografts; Azabicyclo Compounds; Bacteremia; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Febrile Neutropenia; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Retrospective Studies; Tazobactam; Treatment Outcome; Young Adult | 2021 |
Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles.
Topics: Anti-Infective Agents; beta-Lactamase Inhibitors; Cephalosporins; Epidemiological Monitoring; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Polymerase Chain Reaction; Tazobactam; United Kingdom | 2017 |
Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
Topics: Anti-Bacterial Agents; Bacteriological Techniques; Cephalosporins; Clinical Protocols; Drug Combinations; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Male; Metronidazole; Models, Econometric; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quality-Adjusted Life Years; Tazobactam; United Kingdom | 2017 |
Determination of Disk Diffusion and MIC Quality Control Guidelines for High-Dose Cefepime-Tazobactam (WCK 4282), a Novel Antibacterial Combination Consisting of a β-Lactamase Inhibitor and a Fourth-Generation Cephalosporin.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cephalosporins; Disk Diffusion Antimicrobial Tests; Drug Combinations; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Guidelines as Topic; Humans; Penicillanic Acid; Quality Control; Tazobactam | 2017 |
Acute septic arthritis of shoulder joint caused by Aeromonas veronii biotype sobria.
Topics: Acute Disease; Aeromonas veronii; Aged, 80 and over; Arthritis, Infectious; Arthrocentesis; Cefoperazone; Female; Fever; Gram-Negative Bacterial Infections; Humans; Injections, Intravenous; Levofloxacin; Shoulder Joint; Tazobactam; Treatment Outcome | 2018 |
Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Load; beta-Lactamase Inhibitors; Cephalosporins; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Models, Theoretical; Tazobactam | 2018 |
Know your enemy: managing resistant Gram-negative infections.
Topics: Animals; Antimicrobial Stewardship; Azabicyclo Compounds; Carrier State; Ceftazidime; Cephalosporins; Drug Combinations; Drug Development; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Tazobactam | 2018 |
Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Child; Child, Preschool; Europe; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; Infant; Infant, Newborn; Male; Microbial Sensitivity Tests; Prospective Studies; Tazobactam; United States | 2019 |
Antibiotics for Ceftriaxone-Resistant Gram-Negative Bacterial Bloodstream Infections.
Topics: Anti-Bacterial Agents; Bacteremia; Ceftriaxone; Escherichia coli; Gram-Negative Bacterial Infections; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Tazobactam | 2019 |
Antibiotics for Ceftriaxone-Resistant Gram-Negative Bacterial Bloodstream Infections.
Topics: Anti-Bacterial Agents; Bacteremia; Ceftriaxone; Escherichia coli; Gram-Negative Bacterial Infections; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Tazobactam | 2019 |
Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates.
Topics: Anaerobiosis; Anti-Bacterial Agents; Bacteroides fragilis; Cephalosporins; Clostridium; Drug Combinations; Fusobacterium; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Prevotella; Propionibacterium; Tazobactam | 2014 |
Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
Topics: Academic Medical Centers; Anti-Bacterial Agents; Cephalosporins; Cross Infection; Europe; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pneumonia, Bacterial; Tazobactam; United States | 2014 |
Capnocytophaga sputigena bacteremia in a patient with chronic lymphocytic leukemia.
Topics: Adult; Anti-Bacterial Agents; Bone Marrow Transplantation; Capnocytophaga; Gram-Negative Bacterial Infections; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; RNA, Ribosomal, 16S; Sequence Analysis, RNA; Sequence Homology, Nucleic Acid; Tazobactam; Transplantation, Homologous; Treatment Outcome | 2014 |
Catheter-related bacteremia by Cupriavidus metallidurans.
Topics: Adult; Aged; Bacteremia; Catheter-Related Infections; Cupriavidus; Female; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tazobactam | 2015 |
Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections.
Topics: Animals; beta-Lactamase Inhibitors; Cephalosporins; Clinical Trials as Topic; Enterobacteriaceae; Escherichia coli; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Investigational New Drug Application; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2015 |
Influence of antimicrobial consumption on gram-negative bacteria in inpatients receiving antimicrobial resistance therapy from 2008-2013 at a tertiary hospital in Shanghai, China.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Ceftazidime; China; Ciprofloxacin; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Utilization Review; Escherichia coli; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Inpatients; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Tertiary Care Centers | 2015 |
Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002.
Topics: Acinetobacter baumannii; Anti-Infective Agents; Bacterial Proteins; beta-Lactamases; Drug Therapy, Combination; Enterobacteriaceae; Gram-Negative Bacterial Infections; Half-Life; Humans; Intensive Care Units; Lung Diseases; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Patient Admission; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; United States | 2008 |
Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Female; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Length of Stay; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome | 2009 |
Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
Topics: Adult; Aged; Drug Administration Schedule; Gram-Negative Bacterial Infections; Hospitalization; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Penicillanic Acid; Piperacillin; Tazobactam | 2009 |
An unusual case of septic shock in a geriatric patient.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Antidiuretic Agents; Capnocytophaga; Female; Fluid Therapy; Gram-Negative Bacterial Infections; Humans; Multiple Organ Failure; Penicillanic Acid; Piperacillin; Risk Factors; Shock, Septic; Tazobactam; Vancomycin; Vasopressins | 2010 |
Empiric antibiotics pending bronchoalveolar lavage data in patients without pneumonia significantly alters the flora, but not the resistance profile, if a subsequent pneumonia develops.
Topics: Acetamides; Anti-Bacterial Agents; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Linezolid; Male; Microbial Sensitivity Tests; Middle Aged; Oxazolidinones; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Retrospective Studies; Tazobactam; Treatment Outcome; Vancomycin; Wounds and Injuries | 2013 |
Safety evaluation of piperacillin/tazobactam in very low birth weight infants.
Topics: Anti-Bacterial Agents; Bacteremia; Cross Infection; Drug Therapy, Combination; Enterocolitis, Necrotizing; Female; Gram-Negative Bacterial Infections; Humans; Infant; Infant, Newborn; Infant, Very Low Birth Weight; Male; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam; Treatment Outcome | 2004 |
Successful treatment and limb salvage of mucor necrotizing fasciitis after kidney transplantation with posaconazole.
Topics: Alcaligenes; Amphotericin B; Amputation, Surgical; Antifungal Agents; Cefazolin; Combined Modality Therapy; Debridement; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Combinations; Drug Resistance, Multiple, Fungal; Escherichia coli Infections; Fatal Outcome; Fluconazole; Gangrene; Graft Rejection; Gram-Negative Bacterial Infections; Humans; Immunocompromised Host; Immunosuppressive Agents; Kidney Transplantation; Leg; Leg Ulcer; Male; Middle Aged; Mucor; Mucormycosis; Penicillanic Acid; Phosphatidylcholines; Phosphatidylglycerols; Piperacillin; Postoperative Complications; Pyrimidines; Renal Dialysis; Reoperation; Sepsis; Skin Transplantation; Tazobactam; Triazoles; Voriconazole | 2007 |
[Infection with Aeromonas hydrophila after use of leeches (Hirudo medicinalis) in a free microvascular osteo-(myo-)cutaneous flap--suggestions for successful management].
Topics: Adult; Aeromonas hydrophila; Animals; Anti-Bacterial Agents; Drug Therapy, Combination; Follow-Up Studies; Foot; Gram-Negative Bacterial Infections; Hirudo medicinalis; Humans; Leeching; Male; Penicillanic Acid; Piperacillin; Radiography; Surgical Flaps; Tazobactam; Time Factors; Treatment Outcome | 2007 |
Implementation of antibiotic rotation protocol improves antibiotic susceptibility profile in a surgical intensive care unit.
Topics: Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Clinical Protocols; Critical Care; Cross Infection; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Incidence; Intensive Care Units; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Probability; Retrospective Studies; Sensitivity and Specificity; Tazobactam; Treatment Outcome | 2007 |
Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
Topics: Ampicillin; beta-Lactamase Inhibitors; Cefoperazone; Cephalosporins; Clavulanic Acid; Clavulanic Acids; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Retrospective Studies; Sulbactam; Tazobactam; Ticarcillin; Urinary Tract; Urinary Tract Infections | 1997 |
[Cost of antibiotic therapy in neutropenic patients undergoing peripheral blood stem cell transplantation for breast cancer].
Topics: Amikacin; Antineoplastic Agents; Breast Neoplasms; Drug Costs; Drug Therapy, Combination; Female; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Hematopoietic Stem Cell Transplantation; Hospital Costs; Humans; Neutropenia; Penicillanic Acid; Piperacillin; Spain; Tazobactam; Teicoplanin; Transplantation Conditioning; Treatment Failure; Treatment Outcome; Vancomycin | 2000 |
In vitro susceptibilities of Capnocytophaga isolates to beta-lactam antibiotics and beta-lactamase inhibitors.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Capnocytophaga; Clavulanic Acid; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2000 |